LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
LEXINGTON, Mass., Feb. 17, 2016 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will present at the 2016 RBC Capital Markets Global Healthcare Conference on February 24, 2016, at 11:00 a.m. Eastern Time in New York City.
The presentation will be held using a fireside-chat format in which Dr. Ali Fattaey, President and Chief Executive Officer, will provide a brief overview of the Company’s pipeline of drug candidates and business strategy, after which an equity analyst will moderate a question and answer session.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.veracast.com/webcasts/rbc/healthcare2016/88207347337.cfm
The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
